Site selection for heart failure clinical trials in the USA

Heart Failure Reviews

Volumn 20, Issue 4, 2015, Pages 375-383

  Harinstein, Matthew E ^a   Butler, Javed ^b   Greene, Stephen J ^c   Fonarow, Gregg C ^d   Stockbridge, Norman L ^e   O’Connor, Christopher M ^f   Pfeffer, Marc A ^g   Mehra, Mandeep R ^g   Solomon, Scott D ^g   Yancy, Clyde W ^c   Fiuzat, Mona ^f   Mentz, Robert J ^f   Collins, Sean P ^h   McMurray, John J V ⁱ   Vaduganathan, Muthiah ^j   Dunnmon, Preston M ^e   Rosano, Giuseppe M C ^k   Dinh, Wilfried ^l,m   Misselwitz, Frank ^l   Bonow, Robert O ^c   Gheorghiade, Mihai ^c   more..

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k Scientific Institute   (Italy)

^l BAYER PHARMA AG   (Germany)

^m Witten University   (Germany)

more..

Author keywords

Clinical trials; Heart failure; Outcomes; Site selection; United States

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; COOPERATION; HEALTH CARE COST; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; NORTH AMERICAN; PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; STUDY DESIGN; TOTAL QUALITY MANAGEMENT; TREATMENT FAILURE; UNITED STATES; CLINICAL TRIAL (TOPIC); FEMALE; MALE; PATIENT SELECTION; PROCEDURES;

CLINICAL TRIALS AS TOPIC; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; PATIENT SELECTION; UNITED STATES;

EID: 84930864980     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-015-9473-z     Document Type: Article

References (43)

1. Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125:e2–e220
2. Gheorghiade M, Abraham WT, Albert NM et al (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296:2217–2226
3. Konstam MA, Gheorghiade M, Burnett JC Jr et al (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297:1319–1331
4. Massie BM, O’Connor CM, Metra M et al (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363:1419–1428
5. O’Connor CM, Starling RC, Hernandez AF et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32–43
6. Felker GM, Pang PS, Adams KF et al (2010) Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 3:314–325
7. Gheorghiade M, Adams KF, Cleland JG et al (2009) Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 157:957–970
8. Gheorghiade M, Pang PS, O’Connor CM et al (2011) Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. Am Heart J 161:224–232
9. Gheorghiade M, Zannad F, Sopko G et al (2005) Acute heart failure syndromes: current state and framework for future research. Circulation 112:3958–3968
10. Califf RM, Harrington RA (2011) American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy? J Am Coll Cardiol 58:677–680
11. Eapen ZJ, Vavalle JP, Granger CB, Harrington RA, Peterson ED, Califf RM (2013) Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J 165:837–847
12. Velazquez EJ, Lee KL, Deja MA et al (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364:1607–1616
13. Blair JE, Zannad F, Konstam MA et al (2008) Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan) program. J Am Coll Cardiol 52:1640–1648
14. O’Connor CM, Fiuzat M, Swedberg K et al (2011) Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol 58:915–922
15. MacMahon S, Perkovic V, Patel A (2013) Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. JAMA 310:907–908
16. Glickman SW, McHutchison JG, Peterson ED et al (2009) Ethical and scientific implications of the globalization of clinical research. N Engl J Med 360:816–823
17. Butler J, Fonarow GC, O’Connor C et al (2015) Improving cardiovascular clinical trials in the United States: recommendation from clinicians, researchers, sponsors, and regulators. Am Heart J [in press]
18. Gheorghiade M, Bohm M, Greene SJ et al (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309:1125–1135
19. Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392
20. Shah AM, Shah SJ, Anand IS et al (2014) Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 7:104–115
21. Teerlink JR, Cotter G, Davison BA et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39
22. McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004
23. Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467
24. Butler J, Subacius H, Vaduganathan M et al (2013) Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan) trial. J Am Coll Cardiol 61:571–579
25. Summer R, Wiener RS, Carroll D, Sager A (2012) Physician perception of the impact of productivity measures on academic practice. Arch Intern Med 172:967–969
26. Mezrich R, Nagy PG (2007) The academic RVU: a system for measuring academic productivity. J Am Coll Radiol 4:471–478
27. Gheorghiade M, Vaduganathan M, Greene SJ et al (2014) Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev 19:135–152
28. Dickert NW, Llanos A, Samady H (2012) Re-visiting consent for clinical research on acute myocardial infarction and other emergent conditions. Prog Cardiovasc Dis 55:251–257
29. Shahzad A, Kemp I, Mars C et al (2014) Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 384:1849–1858
30. Harinstein ME, Flaherty JD, Fonarow GC et al (2011) Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart 97:1607–1618
31. Adams KF Jr, Fonarow GC, Emerman CL et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209–216
32. Cleland JG, Swedberg K, Follath F et al (2003) The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24:442–463
33. Gheorghiade M, Pang PS (2009) Acute heart failure syndromes. J Am Coll Cardiol 53:557–573
34. Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI (2008) Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 15:450–457
35. Oliva F, Mortara A, Cacciatore G et al (2012) Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail 14:1208–1217
36. Markman M, Smoyer L, Marron JT, Montgomery R (2007) Cancer versus heart failure patient self-declared potential interest in clinical trials. Curr Oncol Rep 9:1–5
37. Greene SJ, Shah AN, Butler J et al (2014) Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J 168:142–149
38. Hess CN, Rao SV, Kong DF et al (2013) Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the study of access site for enhancement of percutaneous coronary intervention for women (SAFE-PCI for women). Am Heart J 166(421–428):e1
39. Frobert O, Lagerqvist B, Olivecrona GK et al (2013) Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369:1587–1597
40. Svilaas T, Vlaar PJ, van der Horst IC et al (2008) Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358:557–567
41. Lauer MS, D’Agostino RB Sr (2013) The randomized registry trial—the next disruptive technology in clinical research? N Engl J Med 369:1579–1581
42. Eapen ZJ, Lauer MS, Temple RJ (2014) The imperative of overcoming barriers to the conduct of large, simple trials. JAMA 311:1397–1398
43. Reiter KL, Song PH, Minasian L, Good M, Weiner BJ, McAlearney AS (2012) A method for analyzing the business case for provider participation in the National Cancer Institute’s Community Clinical Oncology Program and similar federally funded, provider-based research networks. Cancer 118:4253–4261